(MENAFNEditorial)
The trend of pharmaceutical plant closures in Puerto Rico will lead to increasing unemployment and deterioration of the island's economy over the short term as companies are forced to consolidate their manufacturing operations in the face of financial challenges . In the long term Puerto Rico remains an attractive destination for medicine production as new and renewed investments will continue to enter the country.
Headline Expenditure Projections
* Pharmaceuticals: USD3.020bn in 2013 to USD3.023bn in 2014; +0.1%. Forecast slightly down compared with Q414.
* Healthcare: USD7.76bn in 2013 to USD8.02bn in 2014; +3.4%. Forecast slightly down compared with Q414.
Risk/Reward Index
Puerto Rico is the third most attractive pharmaceutical market in the Americas region behind the US and Canada. Puerto Rico's Pharmaceutical Risk/Reward Index score of 63.8 out of 100 is unchanged from Q414. However its position is threatened by improvements inBrazil Mexico Argentina and Colombia given their lower operating costs and improving business environments.
Full Report Details at
- http://www.fastmr.com/prod/944772_puerto_rico_pharmaceuticals_healthcare_report_q1.aspx?afid=101
Key Trends And Developments
* In December 2014 US-based Romark Laboratories said it will construct a USD110mn facility in Puerto Rico. Construction will start in January 2015 and will employ 200 people within three years.
* In December 2014 Sanofi's animal health company Merial announced it would buy a Merck manufacturing plant in Puerto Rico that was being closed and retain its 200 employees. The plant is expected to manufacture and package Heartgard and Heartgard Plus products.
* In October 2014 Eli Lilly was planning to end operations at its Guayama unit in Puerto Rico the US. The company is seeking to divest the unit because its operations have been hampered due to patent expirations for medicines manufactured at the unit. The plant is expected to continue to operate until the end of 2015 and around 100 employees working at the unit will be offered jobs at another facility in Puerto Rico....
The Puerto Rico Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports focusing on the growth outlook for the prescription OTC patented drugs and generics market segments.
BMI's Puerto Rico Pharmaceuticals & Healthcare Report provides industry professionals strategists company executives investors analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Puerto Rico pharmaceutical and healthcare industry.
Key Benefits
* Benchmark BMI's pharmaceutical and healthcare market forecasts for Puerto Rico to test other views - a key input for successful budgeting and strategic business planning in the Puerto Rican pharmaceutical and healthcare market.
* Target business opportunities and risks in the Puerto Rican pharmaceutical and healthcare sector through our reviews of latest industry trends regulatory changes and major deals projects and investments in Puerto Rico.
* Assess the activities strategy and market position of your competitors via our Company Profiles (inc. SWOTs KPIs and latest activity) and Competitive Landscape Tables.
Coverage
BMI Industry ViewAn at-a-glance perspective on the latest regulatory developments key forecast indicators and major corporate developments covering the prescription OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis and taken together with BMI’s political economic and business environment SWOTs it gives a complete overview of market climate.
BMI Industry Forecast ScenarioIndustry forecasts to end-2019 for all key indicators supported by explicit assumptions plus analysis of key downside risks to the main forecasts:
Healthcare: Total healthcare expenditure (USDbn) healthcare expenditure (% of GDP) healthcare expenditure per capita (USD) hospital beds doctors and birth & mortality rates (all per ‘000 population).Pharmaceutical Market: Drug expenditure in USDbn % of GDP and per capita (USD).Patented Drug Market: Prescription drug sales (USDbn & % of total sales).Generic Drug Market: Generic product sales (USDbn) generic sales (% of total sales).OTC Drug Market: OTC sales (USDbn & % of total sales).Macroeconomic Forecasts: Nominal and real GDP % real GDP growth % private consumption growth % industrial output growth % consumer price index % GDP price deflator exports imports trade balance current account balance foreign direct investment exchange rate against USD government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward IndexBMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry economic and demographic data points to provide indices of highest to lowest appeal to investors with each position explained.
Market SummaryA snapshot of key market characteristics including total size of the pharmaceuticals and healthcare segments growth drivers leading therapeutic areas and the competitive landscape
Industry DevelopmentsA focus on government healthcare reforms epidemiological trends mergers and acquisitions product launches market entries FDI activity R&D biotechnology clinical trials and supply chain issues.
Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services pricing and reimbursements intellectual property taxation and advertising as well as analysis of the overall regulatory burden.
Competitive LandscapeThe competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector as well as the OTC generics and distribution sub-sectors.
Company Profiles*
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts we provide quick and easy access to the best competitive intelligence available. Our unbiased expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.